Folfox or Capox |
9 |
Folfox or Capox + Bevacizumab |
23 |
Folfiri or CapIri |
1 |
Folfiri or CapIri + Bevacizumab |
2 |
Folfiri or CapIri + anti-EGFR |
6 |
Irinotecan + anti-EGFR |
0 |
Fluoropyrimidines monotherapy |
0 |
Fluoropyrimidines + Bevacizumab |
2 |
Anti-EGFR monotherapy |
0 |
Fluoropyrimidines + Mytomicin-C |
0 |
Second-line schedules |
|
Folfox or Capox |
7 |
Folfox or Capox + Bevacizumab |
0 |
Folfiri or CapIri |
8 |
Folfiri or CapIri + Bevacizumab |
2 |
Folfiri or CapIri + anti-EGFR |
15 |
Irinotecan + anti-EGFR |
4 |
Fluoropyrimidines monotherapy |
3 |
Fluoropyrimidines + Bevacizumab |
0 |
Anti-EGFR monotherapy |
1 |
Fluoropyrimidines + Mytomicin-C |
0 |
Third line schedules |
|
Folfox or Capox |
1 |
Folfox or Capox + Bevacizumab |
0 |
Folfiri or CapIri |
3 |
Folfiri or CapIri + Bevacizumab |
0 |
Folfiri or CapIri + anti-EGFR |
0 |
Irinotecan + anti-EGFR |
3 |
Fluoropyrimidines monotherapy |
4 |
Fluoropyrimidines + Bevacizumab |
0 |
Anti-EGFR monotherapy |
6 |
Fluoropyrimidines + Mytomicin-C |
9 |
Re-challenges at any lines of therapy |
21 |